Please login to the form below

Not currently logged in
Email:
Password:

Immunocore names CEO

Eliot Forster is chairman of the MedCity project
Immunocore Eliot Forster

The UK-based biotech Immunocore has appointed industry veteran Dr Eliot Forster as CEO.

Dr Forster will lead the firm, which is focused on the development of biological drugs to treat cancer and viral diseases and has several partnerships in place with major pharma companies including Genentech, GlaxoSmithKline and AstraZeneca.

He joins from his role as CEO of Creablis, a UK biotech with a focus on dermatology and pain management, and he also holds the role of chairman of the UK's MedCity project to grow a life sciences cluster in south east England.

“I am delighted to welcome Eliot Forster to Immunocore, and as a member of the Board,” said Dr Jonathan Knowles, executive chairman of the company. “His significant drug development experience will be invaluable to Immunocore as we continue to deliver within our partnerships and advance our proprietary ImmTAC pipeline."

Dr Forster's experience includes role at the pharma major Pfizer where he served as head of development and operations for its operations in the EU and Pfizer. During this time he helped bring several drugs to markets including Celebrex (celecoxib) and Relpax (eletriptan) and to establish the company in India and China.

13th January 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics